{"filing":{"accession_number":"0001193125-26-254658","cik":"0001213037","ticker":"CRDF","company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"crdf-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526254658/crdf-20260603.htm"},"events":[{"id":7139,"run_id":6264,"accession_number":"0001193125-26-254658","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3940,"accession_number":"0001193125-26-254658","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:22:10.617067+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3940,"accession_number":"0001193125-26-254658","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M\u0026A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:22:10.617067+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-06-03"}]}